Journal
LEUKEMIA RESEARCH
Volume 37, Issue 10, Pages 1195-1199Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2013.06.006
Keywords
Chronic lymphocytic leukemia; Flavopiridol; High-risk cytogenetics; Cyclin-dependent kinase inhibitor; Chemoimmunotherapy; Alvocidib; Del(17p); Del(11q)
Categories
Funding
- Leukemia and Lymphoma Society [K12 CA133250, PO1 CA081534]
- D. Warren Brown Foundation
Ask authors/readers for more resources
Alvocidib has demonstrated efficacy in high-risk chronic lymphocytic leukemia (CLL) patients. In this phase I study, we combined cyclophosphamide, alvocidib and rituximab (CAR) in a schema designed to mitigate tumor lysis syndrome (TLS) seen previously with alvocidib. Nine nucleoside analog-naive, high-risk patients received escalating doses of CAR therapy. Dose limiting toxicity was not experienced. No instances of TLS were observed. Patient responses included three complete remissions and four partial remissions. CAR was tolerable and active in high-risk CLL patients without TLS toxicity. With continued monitoring of toxicities, a phase Ib/II study of this combination as frontline therapy is warranted. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available